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It has become clear from multiple studies that WWOX (WW domain-containing
oxidoreductase) operates as a “non-classical” tumor suppressor of significant relevance
in cancer progression. Additionally, WWOX has been recognized for its role in a much
wider array of human pathologies including metabolic conditions and central nervous
system related syndromes. A myriad of putative functional roles has been attributed to
WWOX mostly through the identification of various binding proteins. However, the reality
is that much remains to be learned on the key relevant functions of WWOX in the normal
cell. Here we employed a Tandem Affinity Purification-Mass Spectrometry (TAP-MS)
approach in order to better define direct WWOX protein interactors and by extension
interaction with multiprotein complexes under physiological conditions on a proteomic
scale. This work led to the identification of both well-known, but more importantly
novel high confidence WWOX interactors, suggesting the involvement of WWOX in
specific biological and molecular processes while delineating a comprehensive portrait
of WWOX protein interactome. Of particular relevance is WWOX interaction with key
proteins from the endoplasmic reticulum (ER), Golgi, late endosomes, protein transport,
and lysosomes networks such as SEC23IP, SCAMP3, and VOPP1. These binding
partners harbor specific PPXY motifs which directly interact with the amino-terminal
WW1 domain of WWOX. Pathway analysis of WWOX interactors identified a significant
enrichment of metabolic pathways associated with proteins, carbohydrates, and lipids
breakdown. Thus, suggesting that WWOX likely plays relevant roles in glycolysis, fatty
acid degradation and other pathways that converge primarily in Acetyl-CoA generation,
a fundamental molecule not only as the entry point to the tricarboxylic acid (TCA) cycle
for energy production, but also as the key building block for de novo synthesis of lipids
and amino acids. Our results provide a significant lead on subsets of protein partners
and enzymatic complexes with which full-length WWOX protein interacts with in order
to carry out its metabolic and other biological functions while also becoming a valuable
resource for further mechanistic studies.
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INTRODUCTION
The WWOX (WW domain-containing OXidoreductase) gene,
spans 1.1Mb, and contains common chromosomal fragile site
FRA16D at ch16q23.1-23.2 (1, 2). It encodes a 414-amino acid,
46-kDa protein composed of two WW domains in tandem
(designated WW1 and WW2) located N-terminal to the short-
chain dehydrogenase/reductase (SDR) domain (1). WWOX was
originally discovered by our laboratory and described by us
and others as a putative tumor suppressor protein mostly
associated with tumor progression, and therapy resistance in
multiple cancer types (3–6). It has become clear by experimental
evidence from multiple studies and human data that WWOX
operates as a “non-classical” tumor suppressor [Reviewed in
(5, 7)], likely of more relevance for affecting tumor progression
rather than cancer initiation. Importantly, over the yearsWWOX
has become recognized for its role in a much wider array of
human pathologies including metabolic conditions and central
nervous system (CNS) related syndromes (5, 8–10). WWOX is
ubiquitously expressed in various tissues and cell types (11) and
has been suggested to play roles in multiple cellular processes
including but not limited to: apoptosis (12, 13); regulating
the availability of various transcription factors, cofactors, and
signaling molecules (14–19), cell adhesion (20, 21), metabolic
functions (5, 10, 22, 23), and maintenance of genomic stability
(6, 24). In most of the described cellular processes, WWOX
was proposed to exert its regulatory/homeostatic roles via direct
protein-protein interactions. Therefore, the apparent versatile
nature ofWWOX can be attributed in part to its ability to interact
with different proteins in multiple cellular pathways. However,
it is noteworthy that the significance of most of the reported
interactions to the most relevant biological functions of WWOX
in the normal cell still remains to be settled.
In early studies, we defined the characteristics of the prime
candidate domains within the WWOX protein structure that
drive protein-protein interactions, i.e., the WW domains. WW
domains are small protein modules named for their unique
structure: two conserved tryptophan (W) residues spaced ∼20–
22 amino acids apart (25). These domains are typically 35–40
amino acids in length and fold into a three-stranded, antiparallel
β-sheet with two ligand-binding grooves (25, 26). WW domains
were originally classified into four classes depending on their
binding affinity to a diverse set of proline-rich ligand consensus
motifs: Group I binding preferentially PPXY (27), Group II
binding PPLP (28) (where P is proline, Y is tyrosine, L is
leucine, and X is any amino acid), Group III binding poly-proline
sequences flanked by Arg or Lys (29), and Group IV binding
phospho-Ser-Pro or phospho-Thr-Pro (30). We determined that
WWOX WW1 domain, conformed by tryptophan (W) residues
at positions 22 and 44, belongs to Group I due to its predilection
for binding proteins harboring PPXYmotifs (31). WWOXWW2
domain is not a classical WW domain due to the replacement of
the second signature tryptophan by a tyrosine at position 85 and
no bindingmotif was identified (31).More recently, it was further
confirmed that theWW2 domain does not bind to any consensus
proline-rich motif, but does augment the ability of WW1 to do so
(32).
The vast majority of studies utilized low throughput
protein-protein interaction assays to identify potential
WWOX interacting partners, such as affinity capture-western,
reconstituted complex, and yeast two-hybrid systems. Only two
high throughput scale studies were reported where GST-fusion
WWOX WW1 domain protein constructs were used as bait and
its interacting partners were precipitated through GST-pulldown
approaches followed by identification using mass spectrometry
(MS) (33, 34). The report of Ingham et al. was done in-vitro
on cell extracts (33) while the study of Abu-Odeh et al. was
done after ectopically expressing a GST-WW1 domain fusion
construct in HEK293 cells followed by GST-pulldown and MS
(34). Although important in their own way, some limitations
are intrinsic to the mentioned approaches and this include: (i)
the use of only a very small portion of the WWOX protein (i.e.,
WW1 domain); (ii) the large size of the fusion GST tag (221
amino acids, 22-kDa) with potential non-physiological folding
of the ectopically expressed fusion protein (i.e., WW1 domain +
GST tag); and (iii) lack of the functional enzymatic SDR domain
known to significantly affect intracellular localization (5, 35).
The key question regarding the myriad of reported WWOX
interacting proteins identified both by low and high throughput
approaches is how many are truly relevant and really reflect
the most important biological functions of WWOX in the
normal cell. It is important to stress that WWOX is also an
enzyme predicted to carry out NAD(H) or NADP(H)-dependent
dehydrogenase reactions with yet to be identified substrate/s, and
undoubtedly this predicted metabolic role of WWOX is likely to
be of much relevance to ultimately answer the aforementioned
question.
The development of high-throughput Tandem Affinity
Purification-Mass Spectrometry (TAP-MS) methods has
revolutionized proteomics research (36, 37). As an unbiased
approach, TAP-MS technology is ideal for the identification of
not only the individual bait interacting proteins but also larger
protein complexes “associated” with specific bait-protein partner
pairs. In this article, we report using a TAP-MS approach with
full-length WWOX protein as bait in order to identify WWOX-
protein/complex interactions under physiological conditions on
a proteomic scale. This work led to the identification of both
well-known and novel WWOX interacting partners, suggesting
the involvement of WWOX in multiple specific biological
and molecular processes while delineating a comprehensive
portrait of WWOX’s protein interaction network (i.e., WWOX
interactome) and becoming a valuable resource for further
mechanistic studies on the key WWOX biological functions.
MATERIALS AND METHODS
Vector Construct, Cell Culture,
Transfection and Clone Selection for
TAP-MS
HEK293T cells stably expressing SBP-S-FLAG (SFB) triple-
tagged WWOX were generated as described previously (38).
Briefly, the cDNA WWOX full reading frame construct (1) was
subcloned into a pDONOR201 vector using Gateway Technology
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(Invitrogen, Carlsbad, CA, United States) as the entry clone.
Next, a lentiviral-gateway-compatible destination vector was
used to recombine WWOX entry clone for expression of a C-
terminal triple (S tag-Flag tag-SBP tag, i.e., SFB) tagged fusion
protein. All constructs were sequence verified. HEK293T cell
line was obtained from the American Type Culture Collection
(ATCC) and maintained in Dulbecco modified essential medium
(DMEM) supplemented with 10% fetal bovine serum at 37◦C
in 5% CO2. Using polyethylenimines the SFB-tagged WWOX
encoding vector construct was transfected into HEK293T cells.
Cells were selected with puromycin, 12 single clones were
picked and examined forWWOX expression byWestern blotting
using anti-FLAG antibody (MilliporeSigma, Burlington, MA,
United States).
Tandem Affinity Purification of WWOX
Interacting Protein/Complexes and MS
Analysis
The TAP-MS procedure has been previously described in detail
(38–41). Briefly, HEK293T cells stably expressing SFB-tagged
WWOX were lysed with NETN lysis buffer. For the first affinity
purification step, crude lysate was subjected to centrifugation
and the supernatant was incubated with streptavidin-conjugated
beads (GE Healthcare, Pittsburg, PA, United States). The beads
were washed three times with NETN buffer, and the bound
proteins were eluted with NETN buffer containing 2 mg/ml
biotin (MilliporeSigma, Burlington, MA, United States). For the
second purification step, eluate obtained in step 1 was incubated
with S protein beads (Novagen, Kenilworth, NJ, United States).
The beads were washed again with NETN buffer thrice and
subjected to SDS-PAGE. The protein band containing the entire
sample was excised, chopped, and gel pieces were subjected to
in-gel trypsin digestion followed by drying. Dried sample was
reconstituted in 5 µl of HPLC solvent A (2.5% acetonitrile, 0.1%
formic acid). A nano-scale reverse-phase HPLC capillary column
was created by packing 5µm C18 spherical silica beads into a
fused silica capillary (100µm inner diameter x ∼20 cm length)
with a flame-drawn tip. After equilibrating the column, the
sample was loaded via a Famos autosampler (LC Packings, San
Francisco, CA, United States) onto the column. A gradient was
created and peptides were eluted with increasing concentrations
of solvent B (97.5% acetonitrile, 0.1% formic acid). As the
peptides eluted, they were subjected to electrospray ionization
and then entered into an LTQ Velos ion trap mass spectrometer
(Thermo Fisher, San Jose, CA, United States).
Peptide sequences (protein identity) were determined by
matching the acquired fragmentation pattern with protein
databases by the software program, SEQUEST (ver. 28) (Thermo
Fisher) and spectral counts were generated. To evaluate
potential protein-protein interactions, assign probabilistic scores
to individual interactions and eliminate non-specific interactions,
the Minkowski distance-based unified probabilistic scoring
environment (MUSE) statistical model was applied. Next, to
remove background noise contaminants the data was analyzed
using the CRAPome database (https://www.crapome.org). The
detailed procedure for CRAPome proteomic data analyses
is described elsewhere (42). Identification of WWOX WW1
domain putative binding motifs in interacting partners was done
using the ExPASy-PROSITE web resource that offers tools for
protein sequence analysis and motif detection (43). Biological
pathway analysis was done using the Innate Database (http://
www.innatedb.com)(44).
Co-immunoprecipitation
Full open reading frame, sequenced verified Myc-DDK-
VOPP1 (Catalog # RC221464), Myc-DDK-SCAMP3 (Catalog
# RC201633), and Myc-DDK-SEC23IP (Catalog # RC209056)
expression construct plasmids were purchased from OriGene
(Rockville, MD, United States). Amino-terminal GFP-WWOX
plasmid construction was previously described (3). Anti-Myc
and anti-GFP antibodies were purchased from Cell Signaling
(Danvers, MA, United States) and Invitrogen (Waltham, MA,
United States), respectively. The anti-WWOX rabbit polyclonal
monospecific primary antibody was developed in our laboratory
(31). For co-immunoprecipitation, HEK293T cells were co-
transfected with either 1 µg of Myc-DDK-VOPP1, Myc-DDK-
SCAMP3, or Myc-DDK-SEC23IP along with 1 µg of GFP-
WWOX plasmid. After 36 h cells were lysed with lysis buffer
(50mM Hepes, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM
EGTA, 1% Triton X-100, 50mM NaF, 2mM Na3VO4, and 10%
glycerol) containing 1 × complete protease inhibitor mixture
(Roche, Indianapolis, IN). After centrifugation (12,000 g at 4◦C
for 10min), total cell lysate supernatant fractions were collected
and ∼600 µg of total protein was incubated with respective
antibodies at a 1:200 dilution for 2 h followed by incubation
with Protein A/G PLUS-Agarose (Santa Cruz, Dallas, TX,
United States) for 16 h at 4◦C on a rotary shaker. Corresponding
IgG (MilliporeSigma, Burlington, MA, United States) was used
as a negative control. Antibody-bound beads were washed three
times and bound protein complexes precipated. A 3.3% of
the total cell lysate was used as input and 50% of immuno-
precipitated protein sample was used for western blotting
using 1:2,000 dilution of anti-Myc, anti-GFP, or anti WWOX
antibodies.
GST Pull-Down Assay
GST-fusion protein constructs: (i) wild-type WW domains, i.e.,
WW1 +WW2 (GST-WW1-2); (ii) mutant WW1 domain (GST-
Mut-WW1), i.e., WW1 W44F/P47A + WW2 WT; (iii) mutant
WW2 domain (GST-Mut-WW2), i.e., WW1 WT + WW2
Y85A/P88A; (iv) WW1 WT (GST-WW1); (v) WW2 WT (GST-
WW2); (vi) and full length wild-type WWOX (GST-WWOX)
were constructed and purified as previously described (31). GST-
fusion proteins were expressed in Escherichia coli strain BL21
and purified as described by the manufacturer (MilliporeSigma,
Burlington, MA, United States). Cleared bacterial lysates from
100ml cultures were made by sonication in PBS containing
1x complete protease inhibitor mixture (Roche, Indianapolis,
IN, United States). GST-fusion proteins were purified using
Glutathione Sepharose 4B (MilliporeSigma, Burlington, MA,
United States). NP-40 to a final concentration of 0.1%. was added
to the bacterial lysates. Cleared total cell lysates from HEK293T
cells were prepared using lysis buffer (50mM Tris–Cl, pH 7.5,
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150mMNaCl, 1mMEDTA, 1% Triton X-100, and 10% glycerol).
GST pull-down assays were performed by addition of 10 µg of
purified GST-fusion protein and 20 µl of Glutathione Sepharose
4B (50% slurry) to 600 µg of total cell lysate from HEK293T
cells. After incubation, overnight at 4◦C with mixing, the beads
were washed three times with cold lysis buffer and once with
cold PBS. Twenty micrograms of bound proteins were separated
by SDS/PAGE and analyzed with Western blotting using 1:2,000
anti-Myc antibody.
Statistical Methods
The comparison of interaction scores between WWOX binding
proteins with- and without-motif was done using statistical
software GraphPad PRISM 7 and the Student’s two-tailed
unpaired t-test was used for comparisons. Statistical values of
the enriched pathways were obtained through analysis with
InnateDB. P < 0.05 were considered significant.
RESULTS
TAP-MS Based Proteomic Profiling of
WWOX Interactome
To obtain a comprehensive view of the human WWOX protein
interactome, we performed TAP-MS analyses as illustrated in
the stepwise summary shown in Figure 1. We used HEK293T
cells stably expressing SBP-S-FLAG (SFB) triple-tagged WWOX
as previously described by expression construct transfections
followed by puromycin selection (38). Twelve cell clones were
isolated and examined for expression levels of tagged WWOX
by immunoblotting and selected those with similar expression
level as the endogenous WWOX protein to proceed with
the TAP steps. Total cell lysates from cells stably expressing
SFB-tagged WWOX were subjected to two rounds of affinity
purifications using streptavidin beads and S-beads, the final
eluate was analyzed by LC-MS/MS. We identified a total of
7,589 peptides from two replicates, corresponding to a total
of 795 proteins in replicate-1 and 594 proteins in replicate-
2 (Supplementary File 1). A total of 1,006 unique interacting
proteins were identified from the sum of both replicates. Next,
to increase the probability of identifying true binding partners
and protein complexes we focused and annotated a total of 383
proteins that were common between replicates 1 and 2 for further
analysis (Figure 1).
In order to refine the list of WWOX interactors, we
further analyzed our dataset using the Contaminant Repository
for Affinity Purification database (https://www.crapome.org).
CRAPome is a web-accessible resource that stores annotated
negative controls generated using 411 affinity purification
based MS experiments performed by the proteomics research
community, and enables analyzing affinity purification based
MS data for ultimately providing a CRAPome frequency score
as described in detail by Mellacheruvu et al. (42). Briefly, a
lower CRAPome frequency score indicates a higher specificity
of the prey protein. From the identified 383 proteins, we
narrowed down the list to 253 proteins with a CRAPome
frequency < 0.2. The data was further shortlisted based on
the MUSE algorithm generated interaction scores (40) thus
FIGURE 1 | TAP-MS based Proteomic Profiling of WWOX Interactome.
Schematic diagram showing the major steps involved in the TAP-MS
procedure and data analysis. HEK293T cells stably expressing WWOX with
C-terminal SFB-tag (Streptavidin binding protein (SBP)-tag, S-tag, and
Flag-tag) were generated by stable transfection and puromycin selection.
Following the described tandem affinity purification steps, purified protein
complexes were identified by mass spectrometry analysis (LC-MS/MS), and
final interacting proteins were identified after proper annotation and MUSE
algorithm-based analysis to define interaction scores. Data annotation was
done using Bioconductor. To remove the non-specific bindings or
contaminants data was analyzed using CRAPome database to obtain a list of
high confidence 216 binding partners. Finally, data were subjected to motif
and pathway analysis.
generating a final list of 216 WWOX prey proteins provided in
Supplementary File 2.
High Confidence WWOX Protein
Interactors
As per analysis with the MUSE algorithm (40), we identified 14
proteins with TAP-MS interaction scores (IS)> 0.3. These targets
have a very high likelihood of being direct WWOX physical
binding partners (Table 1 and Figure 2). An additional set of
18 good candidate WWOX binding proteins with IS < 0.3 and
> 0.2 are also shown in Table 1 and Figure 2. These proteins
have varied functions including signal transduction molecules,
enzymes, nucleic acid binders, or transporters and exhibit
diverse sub-cellular localizations including, cellular membrane,
Frontiers in Oncology | www.frontiersin.org 4 December 2018 | Volume 8 | Article 591
Hussain et al. WWOX Protein Interactome
TABLE 1 | Candidate WWOX interacting proteins with highest confidence interaction scores.
Symbol Protein name Subcellular localization Interaction
score
Candidate binding motifs
DVL2 Disheveled 2 Cytosol/Nucleus/Plasma membrane 1.07 133PPSF136, 565PPPY568,
78LPCF81, 548LPTF551
WBP2 WW domain-binding protein 2 Cytoplasm/Nucleus 0.70 167PPGY170, 176PPEF179,
197PPPY200, 249PPPY252,
250PPYY253
DHRS13 Dehydrogenase/
reductase SDR family member
13
Cytoplasm/Secreted 0.65 –
HIRIP3 HIRA-interacting
protein 3
Nucleus 0.62 –
SEC23IP SEC23-interacting
protein
Endoplasmic reticulum 0.56 164PPSY167
VOPP1 Vesicular,
Overexpressed in
Cancer, Pro-survival Protein 1
Cytoplasmic vesicle membrane 0.51 116PPYY119, 154PPAY157,
162PPPY165
CATSPERE Catsper Channel
Auxiliary Subunit
Epsilon
Plasma membrane 0.45 –
AMOT Angiomotin Cell junction/Tight junction 0.42 239PPEY242, 284PPEY287,
106LPTY109
DVL1 Disheveled 1 Cytosol/Plasma
membrane/Cytoplasmic vesicle
0.42 117PPSF120, 546PPCF549,
550PPAY553, 70LPCF73,
374LPRY377
VARS2 Valyl-tRNA synthetase Mitochondrion 0.39 101PPAY104, 22LPRF25
HPF1 Histone PARylation
Factor 1
Nucleus 0.37 112PPEF115
USP24 Ubiquitin carboxyl-terminal
hydrolase 24
Nucleus 0.33 98PPAY101
SCAMP3 Secretory Carrier Membrane
Protein 3
Endosome/Exosome/Secreted 0.31 50PPAY53, 138LPSF141
DAZAP1 DAZ Associated
Protein 1
Nucleus 0.30 259PPPF262, 287PPQF290,
370PPSY373
DNM1L Dynamin 1 Like protein Cytosol/Peroxisome/Mitochondrion/Golgi
apparatus/
0.27 –
STIP1 Stress Induced Phosphoprotein
1
Nucleus 0.26 –
SPART Spartin Cytoplasm 0.26 171PPAY174, 265PPGF268
PEF1 Peflin Endoplasmic reticulum 0.26 –
TMF1 TATA element
modulatory factor 1
Nucleus/ Golgi apparatus 0.25 –
RBM22 RNA Binding
Motif Protein 22
Nucleus 0.25 376PPGF379, 390PPPF393
LRRCC1 Leucine Rich Repeat
and Coiled-Coil Centrosomal
Protein 1
Cytoskeleton 0.24 180LPGY183
GFPT1 Glutamine-fructose-6-phosphate
aminotransferase 1
Cytosol/Secreted 0.24 –
UPF1 Regulator of non-sense
transcripts 1
Cytoplasm 0.24 1005PPGY1008
HNRL1 Heterogeneous
nuclear
ribonucleoprotein
U-like protein 1
Nucleus 0.23 714PPSY717, 781PPAY784,
834PPYY837, 394LPGF397
DIS3 Ribosomal RNA-Processing
Protein 44
Nucleus 0.23 –
(Continued)
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TABLE 1 | Continued
Symbol Protein name Subcellular localization Interaction
score
Candidate binding motifs
MTCH2 Mitochondrial
Carrier 2
Mitochondrion 0.22 –
ATXN10 Ataxin 10 Cytosol/ Secreted/ Plasma
membrane
0.22 –
BCKDHA Branched Chain
Keto Acid
Dehydrogenase E1,
Alpha Polypeptide
Mitochondrion 0.21 –
ASNS Asparagine
synthetase
Cytosol 0.21 –
NPEPPS Puromycin-Sensitive
Aminopeptidase
Cytosol/ Nucleus 0.20 289LPFY292
FDFT1 Farnesyl-Diphosphate
Farnesyltransferase 1
Endoplasmic reticulum 0.20 –
TARS Threonyl-tRNA Synthetase Cytoplasm 0.20 –
cytoplasm, nucleus, Golgi apparatus, endoplasmic reticulum,
mitochondria, and cell junctions. Not unexpectedly, among the
highest confidence group, we find previously described WWOX
binding proteins such as DVL2, DVL1, and AMOT (17, 34),
with DVL2 displaying by far the strongest interaction score
with WWOX. Other previously described WWOX interactors
can be found in this high confidence dataset such as WBP2
(45), and as will be described below some of these top
candidates were identified as well by a previous high throughput
study (34). However, the vast majority of the 216 proteins
we identified using TAP-MS shown in Supplementary File 2
have not been previously reported as WWOX interactors. It
is worth noting that among the 14 highest confidence protein
interactors (IS > 0.3) 80% (i.e., 11 of 14 proteins) contain
candidate WWOX WW1 domain binding motifs (Table 1,
green bars in the graph- Figure 2). This observation reinforces
the notion that this dataset can help us identify novel and
relevant direct WWOX binding proteins via WW domains.
On the other hand, among the list of top interactors with
IS > 0.2, 15 of 32 proteins do not display canonical WW
domain binding motifs suggesting that physical interactions
may occur via other WWOX protein regions or some of
these prey proteins could be members of larger protein
complexes.
WWOX Physical Interaction With Members
of Protein Complexes Related to Protein
Trafficking From ERES to Golgi and From
Late Endosomes to Lysosomes
We have previously shown that WWOX is predominantly a
cytoplasmic protein localizing to the perinuclear compartment
significantly overlapping with the Golgi region (3, 31).
Interestingly, among the most likely direct WWOX interactors
identified by TAP-MS, at least three proteins are related to the
endoplasmic reticulum (ER), Golgi, late endosomes, protein
transport, and lysosomes networks: SEC23IP (SEC23-interacting
protein), SCAMP3 (Secretory Carrier Membrane Protein 3),
and VOPP1 (Vesicular, Overexpressed in Cancer, Pro-survival
Protein 1). All these WWOX interacting proteins have an IS
> 0.3 and based on PROSITE analyses, all of them contain
canonical WW domain binding motifs (Table 1). We validated
the direct physical interaction of WWOX with these three
proteins by means of co-immunoprecipitation (co-IP) in human
cells. Myc-tagged expression constructs for each protein were
co-transfected with a GFP-tagged WWOX expression vector
in HEK-293T cells. Cell lysates were immunoprecipitated
with anti-Myc or anti-GFP antibodies and immunostained
with anti-Myc or anti-WWOX antibodies. Indeed, co-IP
of WWOX with SEC23IP, SCAMP3, and VOPP1 proteins
demonstrated a strong physical interaction between WWOX
and each of these proteins. Furthermore, reciprocal co-IP
with all of the partners for each interaction was observed
(Figure 3A). Very recently, Bonin et al. (46) have also identified
VOPP1 as a WWOX interactor in human cells by means of
yeast-two hybrids and demonstrated that the WW1 region is
the interacting domain mostly with the 162PPPY165 motif of
VOPP1.
In order to determine whether the observed interaction
of WWOX with SEC23IP and SCAMP3 is also dependent
on WWOX WW1 domain, GST-pull down experiments were
performed. We observed that SEC23IP and SCAMP3 fromHEK-
293T whole cell lysates readily bind to GST-fusion constructs
of full-length wild-type WWOX (GST-WWOX), wild-type GST-
WW1-2, and wild-type GST-WW1 (Figure 3B). On the other
hand, no binding was observed to GST-Mut-WW1 (WW1
W44F/P47A + WW2 WT) or wild-type GST-WW2. Thus,
the interaction with SEC23IP and SCAMP3 is lost when
key functional residues of the WW1 domain are mutated,
while the mutation in the WW2 domain (GST-Mut-WW2)
does not affect the overall binding (Figure 3B). In summary,
these results demonstrate that SEC23IP and SCAMP3 are
indeed novel direct interacting partners of WWOX via WW1
domain.
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FIGURE 2 | High confidence WWOX protein interactors. Graph showing
candidate WWOX interacting partners with interaction score (IS) > 0.2. Bars in
green represent the set of 14 proteins with an extremely high likelihood of being
direct physical WWOX binding proteins with IS > 0.3. Bars in blue represent
good candidate WWOX direct binding proteins with IS < 0.3 and > 0.2.
Numbers in parenthesis next to bars represent the number of potential WWOX
binding motifs for each respective interacting protein. The orange line graph
represents CRAPome frequency for each WWOX binding protein.
WWOX WW1 Binding Motifs in TAP-MS
Dataset
A previous study by Abu-Odeh et al. (34) employed an MS-
based screen utilizing GST-WWOX WW1 domain constructs
as bait which confirmed the predilection of the WW1 domain
to bind proteins with PPXY motifs. However, they also
observed that many of WWOX WW1 interacting proteins
did not contain PPXY motifs but exhibited instead PPXF,
LPXY, or LPXF motifs suggesting that the WW1 domain
FIGURE 3 | (A) Direct physical interaction between WWOX and SEC23IP,
SCAMP3, and VOPP1 proteins. Reciprocal co-immunoprecipitation of
GFP-WWOX and Myc-SEC23IP, Myc-SCAMP3 or Myc-VOPP1 in HEK293T
cells. Cells were co-transfected with either 1 µg of Myc-DDK-VOPP1,
Myc-DDK-SCAMP3, or Myc-DDK-SEC23IP along with 1 µg of GFP-WWOX
plasmid. After 36 h transfected cells were lysed and were immunoprecipitated
with either rabbit IgG (control), anti-Myc, or anti-GFP antibodies. The
immunoprecipitates were immunoblotted with anti-Myc or anti-WWOX
antibodies as indicated. (B) Western blot and corresponding Coomassie blue
staining of GST pull-down assay. HEK293T cells were transfected with either
Myc-SEC23IP or Myc-SCAMP3 expression vectors. Cell lysates were
subjected to pulldowns with the indicated GST fusion proteins: either wild-type
WW domains, i.e., WW1 + WW2 (GST-WW1-2); mutant WW1 domain
(GST-Mut-WW1), i.e., WW1 W44F/P47A + WW2 WT; mutant WW2 domain
(GST-Mut-WW2), i.e., WW1 WT + WW2 Y85A/P88A; WW1 WT (GST-WW1),
WW2 WT (GST-WW2), full length wild-type WWOX (GST-WWOX), or GST
alone. Bound protein was detected by anti-Myc immunoblot.
of WWOX binds also non-canonical class 1 WW proline-
containing motifs. We examined the prevalence of potential
WW domain binding motifs as defined in the aforementioned
study among the 216 proteins identified in our TAP-MS
experiment. Analysis of these candidate WWOX interacting
partners using PROSITE showed that 31% (67 out of 216)
proteins contained canonical WW1 domain putative PY
binding motifs as well as other proline-containing motifs
(Figure 4A), as previously described (34). Of a total of 67
proteins, 12 candidate WWOX binding partners displayed
both PPX(Y/F) and LPX(Y/F) motifs (Figure 4A). Thirty-
nine proteins displayed PPX(Y/F) motifs at 56 sites and 40
proteins displayed LPX(Y/F) motifs at 49 sites (Figure 4B
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FIGURE 4 | WW domain binding motifs in WWOX interacting proteins. (A) ExPASY PROSITE analysis was performed on the list of 216 WWOX interactors
(Supplementary File 2). Candidate WWOX WW1 domain binding motifs were identified in 31% (67 out of 216) proteins. Out of 67 proteins with putative WW1
binding motifs, 12 candidate WWOX binding interactors displayed both PPX(Y/F) and LPX(Y/F) motifs. (B) Amino acid sequence of candidate WWOX WW1 domain
binding motifs. The probability of the residue at each position is proportional to the size of the letters. The image was generated using the Weblogo 3.4 program.
Thirty-nine proteins displayed PPX(Y/F) motifs at 56 sites and 40 proteins displayed LPX(Y/F) motif at 49 sites. (C) Box and whisker plot showing the comparison of
median interaction scores between proteins with- and without-motifs. Proteins with-motifs display higher interaction scores (mean interaction score = 0.1875) vs.
proteins with No-motifs (mean interaction score = 0.1287). Statistical analysis was done using two-tailed unpaired Student’s t-test, **p < 0.001. (D) Comparison of
SFB-WWOX-TAP-MS data with GST-WW1-pull-down-MS data from Abu-Odeh (34). Only 16 common WWOX interactors were identified overlapping both datasets.
(E) Bar graph showing a comparison of the percentage of proteins with WWOX binding motifs between the aforementioned datasets. Thirty-one percent of proteins
from the SFB-WWOX-TAP-MS dataset (this study) displayed candidate WW1 binding motifs vs. 46.8% of proteins in the GST-WW1-pull-down-MS dataset (34).
and Supplementary File 3). Notably, 69% (149 out of 216)
WWOX candidate binding proteins were devoid of any
putative WW1 domain binding motifs. We compared the
interaction scores of proteins with- and without-motifs.
Proteins with-motifs displayed a significantly higher
interaction score (mean interaction score = 0.1875, p <
0.001) as compared to proteins with no-motifs (mean
interaction score = 0.1287, Figure 4C), thus suggesting
as expected a higher affinity for direct physical WWOX
binding.
We also compared our full-length WWOX TAP-MS dataset
with the previous GST-WW1 pull-down report (34). In the
Abu-Odeh et al. study 218 WWOX interactors were identified as
reported in BioGRID (https://thebiogrid.org/) (34). Surprisingly,
we identified only 16 common interactors (Table 2 and
Figure 4D) comparing both studies. Eight of these 16 proteins
were also found among our high-to-good confidence candidate
WWOX binding proteins with interaction scores >0.2. Ten of
these 16 proteins harbored candidate proline-containing binding
motifs (Table 2). We also compared the prevalence of candidate
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TABLE 2 | Common WWOX interactors identified in TAP-MS (this study) and Abu-Odeh et al. (34) datasets.
Symbol Protein name Interaction score Binding motifs
DVL2 Disheveled 2 1.07 Yes
WBP2 WW domain-binding protein 2 0.70 Yes
SEC23IP SEC23-interacting protein 0.56 Yes
DVL1 Disheveled 1 0.42 Yes
AMOT Angiomotin 0.42 Yes
DAZAP1 DAZ Associated Protein 1 0.30 Yes
SPART/ SPG20 Spartin 0.26 Yes
HNRL1/ HNRNPUL1 Heterogeneous nuclear
Ribonucleoprotein U-like protein 1
0.23 Yes
FARSA Phenylalanine-tRNA ligase alpha subunit 0.16 –
ATP2A1 Endoplasmic reticulum calcium ATPase 1 0.15 –
HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 0.13 –
RAPGEF2 Rap guanine nucleotide exchange factor 2 0.12 Yes
TARDBP TAR DNA-binding protein 43 0.09 –
ATAD3A ATPase family AAA domain-containing
protein 3A
0.08 –
HADHA Trifunctional enzyme subunit alpha,
mitochondrial
0.06 –
CYFIP1 Cytoplasmic FMR1-interacting protein 1 0.04 Yes
WWOX WW1 binding motifs among the putative interactors
between the two datasets (Figure 4E).
Metabolic Pathways Associated With
WWOX Protein Interactome
In order to investigate if any biological pathways are significantly
over-represented within the list of 216 TAP-MS identified
WWOX binding proteins, we used the Innate Database
(http://www.innatedb.com) (44). Among the most significantly
associated pathways we identified key metabolic pathways
including: “Valine, Leucine, and Isoleucine degradation” (KEGG
pathway hsa00280), “Glycolysis/Gluconeogenesis” (KEGG
pathway hsa00010), “Pyruvate metabolism” (KEGG pathway
hsa00620), and “Fatty acid degradation” (KEGG pathway
hsa00071) (Figure 5A and Supplementary File 4). Interestingly,
all these highly significant pathways that derive from proteins,
carbohydrates, and lipids breakdown converge primarily in
Acetyl-CoA generation, the key molecule that delivers its acetyl
group for oxidation and energy production to the tricarboxylic
acid (TCA) cycle (Figure 5B) and notably at least 22 of the
216 high confidence proteins (Supplementary File 2), play key
enzymatic roles in the identified pathways, mostly as members of
larger enzymatic complexes (marked in red in Figure 5B).
DISCUSSION
TAP-MS utilizing full-length WWOX as a bait under
physiological conditions was employed in order to better
define specific WWOX protein interactors and by extension
interaction with multiprotein complexes. This work led to the
identification of both well-known, but more importantly novel
high confidence WWOX interactors, suggesting the involvement
of WWOX in specific biological and molecular processes
while delineating a comprehensive portrait of WWOX protein
interactome.
We identified endoplasmic reticulum (ER), Golgi, late
endosomes, protein transport, and lysosomes networks related
proteins SEC23IP, SCAMP3, and VOPP1 as direct binding
partners of WWOX with high interaction scores > 0.3 (Figure 2
and Table 1). SEC23IP is localized to ER exit sites (ERES) as
part of the multimeric protein complex II (COPII) that coats
protein transport vesicles and plays a critical function in ER to
Golgi protein transport (47, 48). PROSITE analysis identified a
candidate WWOX WW1 domain binding motif at 164PPSY167
residues within a larger proline-rich region (AA 135–259) of
SEC23IP and importantly this same protein region was shown to
be responsible for the binding to SEC23P (47). In early reports,
we demonstrated that indeed WWOX predominantly localizes
to the perinuclear Golgi region (3, 31). We now demonstrated
that WWOX directly binds to SEC23IP via WW1 domain.
Thus, it is possible to speculate that the WWOX-SEC23IP
interaction might modulate binding of SEC23IP to the COPII
complex and play an important role in ERES assembly or cargo
transport.
SCAMPs are present in all post-Golgi cycling membranes
and colocalize with endosomal markers thus functioning in
vesicular transport. It was shown that SCAMP3 interacts with
endosomal sorting complexes required for transport (ESCRT)
components and plays a role in the biogenesis of multivesicular
endosomes (49) and as a regulator of endosomal morphology
and composition (50). SCAMP3 was suggested to be involved in
negatively regulating epidermal growth factor receptor (EGFR)
degradation and promoting its recycling (51). Here we showed
that WWOX binds to SCAMP3 viaWW1 domain, likely binding
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FIGURE 5 | Metabolic Pathways significantly associated with WWOX protein interactome. (A) Bar graph represents biological pathways that are significantly
over-represented within the list of 216 WWOX interactors. See Supplementary File 4 for detail of interactors and p-values of pathway shown (B) Among the most
significantly associated pathways we identified key metabolic pathways including: “Valine, Leucine, and Isoleucine degradation” (KEGG pathway hsa00280),
“Glycolysis/Gluconeogenesis” (KEGG pathway hsa00010), “Pyruvate metabolism” (KEGG pathway hsa00620), and “Fatty acid degradation” (KEGG pathway
hsa00071). All pathways converge to Acetyl-CoA generation the key molecule that delivers its acetyl group for oxidation and energy production to the tricarboxylic
acid (TCA) cycle. WWOX interactors identified in our TAP-MS dataset are highlighted in red.
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one of two candidate SCAMP3 WW1 binding motifs at residues
50PPAY53 or 138LPSF141.
VOPP1 previously also known as ECOP (EGFR-co-amplified
overexpressed protein) was found amplified and overexpressed in
multiple malignancies and thus considered to be pro-oncogenic
(52, 53). VOPP1 protein structure includes a transmembrane
domain and it was reported to partially co-localize with
perinuclear lysosomes, suggesting that VOPP1 containing
vesicles enter and participate in final lysosomal pathways (54).
Very recently, Bonin et al. (46). using a yeast-two-hybrid
system and co-IP reported that VOPP1 physically interacts with
WWOX. They further described that upon binding, WWOX
translocates to the VOPP1-containing lysosomal compartment
and proposed that VOPP1 behaves as a negative regulator
of WWOX tumor suppressor activity via this protein-protein
sequestration mechanism (46). Independently, our TAP-MS
studies confirmed the observations of Bonin and colleagues
and validated as well the interaction by means of reciprocal
co-IP assays. Of the three candidate VOPP1 PY motifs found
at residues 116PPYY119, 154PPAY157 and 162PPPY165 it was
concluded that the latter one was the most relevant for the
interaction between these two proteins (46).
Interestingly, we have also previously shown an interaction of
endogenously expressedWWOXwith SIMPLE (small membrane
protein of the lysosome/late endosome), which also plays a
role in endosomal protein trafficking and in targeting proteins
for lysosomal degradation (31). This in conjunction with the
aforementioned observations involving SEC23IP, SCAMP3, and
VOPP1 suggest that indeed WWOX is a prime candidate to play
a relevant role in the homeostasis and regulation of perinuclear
protein complexes related to protein trafficking between ERES to
Golgi and from late endosomes to lysosomes.
It is noteworthy that only 16 common WWOX interactors
were identified between the high throughput screen of Abu-
Odeh et al. (34) and our study. Most of the identified interactors
do not overlap between both datasets (Figure 4D). The causes
that may account for such lack of overlap between both datasets
could be due to differences in the methodological approach to
identify WWOX binding partners. Abu-Odeh et al. used ectopic
expression of a GST-WW1 domain fusion construct (i.e., using
only a small portion of WWOX) followed by GST-pulldown and
MS, while we used a full-length WWOX protein construct for
our TAP-MS approach. The latter approach likely assures proper
protein folding and very importantly counts with the presence of
the active SDR domain which can be highly significant for proper
WWOX intracellular localization (5, 35).
We believe that since TAP-MS was performed under in-cellulo
physiological conditions, much relevant information can be
gained from analyzing the data in toto as a portrait for identifying
protein networks, pathways and cellular compartments in
which WWOX likely plays a functional role. Indeed, when
performing pathway analyses ofWWOX interactors we identified
a significant enrichment of metabolic pathways associated
with proteins, carbohydrates and lipids breakdown. Thus,
suggesting that WWOX likely participates in glycolysis, fatty
acid degradation and other pathways that converge primarily in
Acetyl-CoA generation
It is particularly intriguing that practically all members of
the Pyruvate Dehydrogenase Complex (PDC), in charge of
the enzymatic steps that catalyze the conversion of pyruvate
(generated from glycolysis) into acetyl-CoA, can be found
among the 216 proteins (Supplementary File 2), these include
the PDHA1 and PDHB subunits of pyruvate dehydrogenase
(i.e., PDC component E1), DLAT (dihydrolipoamide
acetyltransferase, i.e., PDC component E2), and DLD
(dihydrolipoamide dehydrogenase, i.e., PDC component E3).
Furthermore, PDHA2 the only missing component of PDC E1,
although it did not make the list of 216 proteins it was detected
in replicate-1 of the TAP-MS analysis (Supplementary File 1).
Additionally, PDK3 (pyruvate dehydrogenase kinase 3, not
shown in Figure 5B) can also be found within our dataset
(Supplementary File 2).
Wwox KOmice display abnormalities associated to metabolic
processes including severe hypoglycemia, metabolic acidosis and
additional metabolic abnormalities that lead to early death at
3–4 weeks of age, however although informative, these mouse
models have been of limited used to fully understand the
normal biological role of WWOX (16, 55). Importantly, evidence
suggesting a direct link between WWOX loss of function and
alterations in cellular respiration has been argued (7, 56).
Strikingly similar to our TAP-MS findings, O’Keefe et al. (57) by
using D. melanogaster (DMel) Wwox mutant models, observed
that a significant number of Wwox interactors identified by
a limited proteomic screen are either directly or indirectly
related to metabolic pathways that precisely converge in the
TCA cycle as in our findings (Figure 5B). These include many
enzymes associated with glucose metabolism, lipid metabolism,
ethanol metabolism, and oxidation/reduction, thus suggesting a
contributing function of Wwox associated with the maintenance
of aerobic metabolism (57). Furthermore, from analyzing the
candidate Wwox protein interactors reported by O’Keefe et al.
several orthologs and potential orthologs can be identified that
closely match several of the targets identified by TAP-MS in
our study. Of particular relevance is the finding of interactor
DMel protein CG7430 which is the ortholog of human DLD
(dihydrolipoamide dehydrogenase) precisely the E3 component
of the Pyruvate Dehydrogenase Complex found in our dataset
and discussed in a previous paragraph. The Drosophila
proteomic screen also identified Wwox interactor CG7470 (57)
ortholog of human ALDH18A1 (aldehyde dehydrogenase 18
family member A1) also found in our dataset. Various other
aldehyde dehydrogenases can be found in both datasets, enzymes
of much relevance in pyruvate metabolism, alcohol metabolism,
fatty acids degradation and amino acids degradation (Figure 5B).
Examples include Drosophila Wwox interactors DMel CG3752
and CG31075 with significant similarity to ALDH1B1 a member
of enzymatic complex IUBMB/KEGG EC 1.2.1.3 also known
as aldehyde dehydrogenase (NAD). Two other members of
EC 1.2.13, ALDH3A2 and ADH7A1 are also found in our
dataset (Supplementary File 2 and Figure 5B). This enzymatic
complex plays roles in all the metabolic pathways described
and shown in Figure 5B and in multiple other metabolic
reactions. In conjunction, studies in human cells and Drosophila
indicate that WWOX appears to play critical roles in glucose,
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lipid metabolism and other pathways that converge primarily
in acetyl-CoA generation, which is not only the entry point
to the TCA cycle for energy production, but also the key
building block for the de novo synthesis of lipids and amino
acids.
In agreement with the suggestion of WWOX playing a role
or modulating cellular respiration, Abu-Remaileh and Aqeilan
reported that Wwox KO mouse embryo fibroblasts displayed
increase glucose uptake, enhanced glycolysis and reduced
mitochondrial respiration resembling a “Warburg effect” like
condition. It was also found that WWOX deficiency correlates
with enhanced levels and activity of HIF1α over specific
transcriptional targets related to glycolysis and that WWOX
physically interacts with HIF1α. Based on these observations it
was proposed that WWOX, via modulating HIF1α availability,
might regulate glucose metabolism and that WWOX loss leads
to activation of anaerobic glycolysis (Warburg effect) (22, 56).
However, the exact mechanisms on how WWOX could affect
HIF1α activity and in turn modulate cellular respiration are not
clear. The association of WWOX and the described metabolic
pathways also appear consistent with studies that have shown a
link between WWOX and metabolic-syndrome related human
traits (5, 10, 58). We also observed that gene expression
profiles on samples from liver-specific Wwox conditional KO
mice displayed significantly altered lipid metabolic profiles and
increased plasma triglyceride levels, suggesting a significant role
for WWOX in modulating lipid metabolism (10).
In summary, our results provide a significant lead on subsets
of protein partners and enzymatic complexes with whichWWOX
might interact with in order to carry out its metabolic functions
and other significant biological roles.
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